e-learning
resources
European Respiratory Review
2018
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Interpreting risk reduction in clinical trials for pulmonary arterial hypertension
Annie C. Lajoie, Sébastien Bonnet, Yves Lacasse, Jean-Christophe Lega, Steeve Provencher
Source:
Eur Respir Rev, 27 (148) 180020; 10.1183/16000617.0020-2018
Journal Issue:
June
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Annie C. Lajoie, Sébastien Bonnet, Yves Lacasse, Jean-Christophe Lega, Steeve Provencher. Interpreting risk reduction in clinical trials for pulmonary arterial hypertension. Eur Respir Rev, 27 (148) 180020; 10.1183/16000617.0020-2018
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Developing the pneumonia-optimized ratio for community-acquired pneumonia: an easy, inexpensive and accurate prognostic biomarker
Relationship of respiratory disorders of sleep with cognitive impairment and neurological diseases
Psychological features in smokers: A cross-sectional study using symptom checklist-90-revised
Related content which might interest you:
Do we need controlled clinical trials in pulmonary arterial hypertension?
Source: Eur Respir J 2001; 17: 1-3
Year: 2001
New perspectives in long-term outcomes in clinical trials of pulmonary arterial hypertension
Source: Eur Respir Rev 2013; 22: 495-502
Year: 2013
End-points and clinical trial design in pulmonary arterial hypertension: have we made progress?
Source: Eur Respir J 2009; 34: 231-242
Year: 2009
Pulmonary pressure at rest and during slight exercise might have prognostic relevance in patients at risk for pulmonary arterial hypertension
Source: Annual Congress 2008 - Pulmonary arterial hypertension and other pulmonary vascular diseases
Year: 2008
Early improvements predict outcomes in pulmonary arterial hypertension
Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension
Year: 2018
The future of treatment for pulmonary arterial hypertension
Source: School Course 2014 - Pulmonary Hypertension and Pulmonary Vascular Disease
Year: 2014
The future of treatment for pulmonary arterial hypertension
Source: ERS Course 2017 - Pulmonary Hypertension and Pulmonary Vascular Disease
Year: 2017
The future of treatment for pulmonary arterial hypertension
Source: School Course 2012 - Pulmonary hypertension and pulmonary vascular disease
Year: 2012
The future of treatment for pulmonary arterial hypertension
Source: ERS Skills course - Pulmonary hypertension and pulmonary vascular disease
Year: 2018
Observational trials in pulmonary arterial hypertension: low scientific evidence but high clinical value
Source: Eur Respir J 2007; 29: 432-434
Year: 2007
Comparison of clinical characteristics in patients with pulmonary arterial hypertension and inoperable chronic thromboembolic pulmonary hypertension
Source: Annual Congress 2008 - Pulmonary venous thromboembolic disease
Year: 2008
Clinical trials in pulmonary arterial hypertension: what do they tell us
Source: ERS Skills course - Pulmonary hypertension and pulmonary vascular disease
Year: 2018
Clinical trials in pulmonary arterial hypertension: what do they tell us
Source: ERS Course 2017 - Pulmonary Hypertension and Pulmonary Vascular Disease
Year: 2017
Clinical trials in pulmonary arterial hypertension: what they tell us
Source: ERS Course 2020 - Pulmonary hypertension and pulmonary vascular disease
Year: 2020
Risk assessment in pulmonary arterial hypertension
Source: Eur Respir Rev 2016; 25: 390-398
Year: 2016
Risk assessment in pulmonary arterial hypertension
Source: Eur Respir J, 51 (3) 1702606; 10.1183/13993003.02606-2017
Year: 2018
Risk assessment in pulmonary arterial hypertension
Source: Eur Respir J, 51 (3) 1800279; 10.1183/13993003.00279-2018
Year: 2018
Long-term safety and clinical effects of riociguat in chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: Interim analysis of a phase II extension study
Source: Annual Congress 2010 - Pulmonary hypertension updates
Year: 2010
Clinical trial design and new therapies for pulmonary arterial hypertension
Source: Eur Respir J, 53 (1) 1801908; 10.1183/13993003.01908-2018
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept